New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
16:04 EDTARRYArray BioPharma to initiate Phase 3 trial evaluating MEK162
Array BioPharma announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer during the summer of 2013. The study, called MILO, will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food and Drug Administration and the European Medicines Agency. Array invented MEK162 and licensed worldwide rights to develop and commercialize the drug to Novartis in April 2010. The MILO study follows a recent announcement by Novartis detailing plans to initiate Phase 3 trials of MEK162 in both NRAS- and BRAF-mutant melanoma and will be covered as part of the Novartis/Array co-development agreement under which costs are capped annually and in total for Array.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
12:28 EDTARRYOptions with increasing implied volatility
Options with increasing implied volatility: THRX ARRY AKRX DECK HSBC
April 21, 2015
13:03 EDTARRYLoxo Oncology reports encouraging initial results from study for LOXO-101
Subscribe for More Information
April 20, 2015
07:20 EDTARRYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 16, 2015
10:51 EDTARRYOptions with increasing implied volatility
Options with increasing implied volatility: PNK ARRY FOSL NSAM WUBA ARCP CSCO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use